SynthesisJournal of clinical hypertension (Greenwich, Conn.)2006
A meta-analysis of the effect of thiazolidinediones on blood pressure.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus.Diabetes, obesity & metabolism · 2026Pooled it
- [Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)].Wiener klinische Wochenschrift · 2023Guideline
- Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.Diabetologia · 2012Trial
- Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.Journal of endocrinological investigation · 2006Trial
- Prevalence of diabetes/prediabetes and their associated risk factors among adults with hypertension from iran: a nationwide study.Scientific reports · 2026Article
- The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.Current obesity reports · 2025Review
- Is fluid retention a cardiovascular risk factor?Clinical hemorheology and microcirculation · 2024Review
- Pioglitazone in diabetic kidney disease: forgotten but not gone.Archives of medical sciences. Atherosclerotic diseases · 2022Article
- A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease.Clinical kidney journal · 2021Article
- Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone.Clinical kidney journal · 2021Article
- Salt-Sensitivity of Blood Pressure and Insulin Resistance.Frontiers in physiology · 2021Review
- [Austrian Consensus on High Blood Pressure 2019].Wiener klinische Wochenschrift · 2019Article
- Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.International journal of molecular sciences · 2019Review
- [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)].Wiener klinische Wochenschrift · 2019Review
- Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.Heart failure reviews · 2018Review
- Cardiovascular effects of anti-diabetes drugs.Expert opinion on drug safety · 2016Review
- Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?Current hypertension reports · 2013Review
- Setting the record straight on TIDE: a lost opportunity for patients with diabetes.Diabetologia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In epidemiologic studies, insulin resistance is associated with hypertension. Thiazolidinediones (TZDs) are antidiabetic agents that decrease insulin resistance. Multiple clinical trials have evaluated the effect of TZDs on blood pressure (BP) with inconsistent results. The aim of this study was to estimate the effect of TZDs on BP. The authors searched PubMed for clinical trials published in English. A total of 37 clinical trials that reported a change in BP were included in the analysis. Trials with independent-group design and trials with pre-post design were evaluated separately. When compared with baseline, TZDs lowered systolic BP by 4.70 mm Hg (95% confidence interval, -6.13 to -3.27) and diastolic BP by 3.79 mm Hg (95% confidence interval, -5.82 to -1.77). When compared with placebo, TZDs lowered systolic BP by 3.47 mm Hg (95% confidence interval, -4.91 to -2.02) and diastolic BP by 1.84 mm Hg (95% confidence interval, -3.43 to -0.25). Thus, TZDs lower both systolic and diastolic BP, albeit the BP-lowering effect is small and may not be of clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.